<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304239</url>
  </required_header>
  <id_info>
    <org_study_id>PC T405/05</org_study_id>
    <nct_id>NCT00304239</nct_id>
  </id_info>
  <brief_title>Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp</brief_title>
  <official_title>A Multicenter, Double Blind, Vehicle-controlled, Randomized Study of Photodynamic Therapy (PDT) With Metvix 160 mg/g Cream and Aktilite CL128 LED Light in Patients With Multiple Actinic Keratosis on the Face and/or Scalp</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of Photodynamic Therapy (PDT) with&#xD;
      methyl aminolevulinate (MAL) cream to PDT with vehicle cream, using the the LED light source&#xD;
      Aktilite CL128, in treatment of patients with multiple actinic keratosis (sun-damaged skin)&#xD;
      on the face and / or scalp.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Actinic keratoses are pre-malignant skin lesions, which may develop to squamous cell&#xD;
      carcinomas (SCC). They are usually small, thin, erythematous, de-squamating lesions on light&#xD;
      exposed atrophic skin and the lesions are often multiple.&#xD;
&#xD;
      Photodynamic therapy (PDT) is the selective destruction of abnormal cells through light&#xD;
      activation of a photosensitiser in the presence of oxygen. These cells accumulate more&#xD;
      photosensitiser than normal cells. The photosensitiser generates reactive oxygen species upon&#xD;
      illumination.&#xD;
&#xD;
      For skin diseases, such as actinic keratosis (AK), there has been an increasing interest in&#xD;
      using topically applied precursors of the photoactive porphyrins (PAP). The most commonly&#xD;
      used precursors have been 5-aminolevulinic acid (ALA) and its derivatives. The present test&#xD;
      drug contains methyl aminolevulinate, which penetrates the lesions well and shows high lesion&#xD;
      selectivity.&#xD;
&#xD;
      Different light sources (i.e. CureLight, Aktilite CL16 and Aktilite CL128) have been used for&#xD;
      the activation of PAP, which absorbs light in the range of 400-700 nm. The present study uses&#xD;
      the Aktilite CL 128 lamp. Aktilite 128 is based on LED technology and emits a narrow red&#xD;
      light spectrum with an average wavelength of 630 (+/-5) nm. This study is similar to two&#xD;
      other studies performed, on which the U.S. approval of Metvixia® cream is based except for&#xD;
      the light source used. This study is one of two studies performed to document the safety and&#xD;
      efficacy of the Aktilite CL 128 lamp when used in combination with Metvixia® cream.&#xD;
&#xD;
      Previous studies have shown that the risks attributed to Metvixia® PDT are few and related&#xD;
      mainly to transient pain and local erythema during and shortly after treatment. These&#xD;
      reactions are part of the expected local phototoxicity reaction. PDT offers an advantage to&#xD;
      other treatment modalities for actinic keratosis, being a non-invasive treatment available on&#xD;
      an outpatient basis. Several separate lesions can be treated simultaneously and the same&#xD;
      lesion(s) can be treated repeatedly with success. There are no known systemic toxicity or&#xD;
      interaction with other medication. The treatment is also lesion selective, leaving the&#xD;
      surrounding tissue intact and functional, also allowing excellent cosmetic results after&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome: To compare the patient complete response rate of MAL PDT to that of vehicle PDT 3 months after the last treatment in patients with multiple actinic keratoses on the face and/or scalp</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcomes: To compare local Adverse Events (treatment site Adverse Events (AEs) between MAL PDT and vehicle PDT; To compare the lesion complete response rate between MAL PDT and vehicle PDT 3 months after last treatment</measure>
  </secondary_outcome>
  <enrollment>80</enrollment>
  <condition>Actinic Keratosis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photodynamic therapy with methyl aminolevulinate cream</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of 4-10 previously untreated, not pigmented, non-hyperkeratotic AK&#xD;
             lesions of 3 mm or more diameter of Grade 1 and/or 2 of the face and/or scalp where&#xD;
             other therapies are unacceptable or considered medically less appropriate.&#xD;
&#xD;
          -  Males or females above 18 years of age.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with porphyria.&#xD;
&#xD;
          -  Patients immunosuppressed for idiopathic, disease specific or therapeutic reasons.&#xD;
&#xD;
          -  Known allergy to MAL, a similar PDT compound or excipients of the cream.&#xD;
&#xD;
          -  Patients with history of hypersensitivity to nut products or other known protein&#xD;
             antigens.&#xD;
&#xD;
          -  Participation in other clinical studies either currently or within the last 30 days.&#xD;
&#xD;
          -  Patients receiving local treatment (including cryotherapy and curretage) in face /&#xD;
             scalp area within the last 30 days.&#xD;
&#xD;
          -  Patients receiving topical treatment (including imiquimod, 5-FU and diclofenac) in&#xD;
             face / scalp area within the last 3 months.&#xD;
&#xD;
          -  Pregnant or breast-feeding: All women of child-bearing potential must use adequate&#xD;
             contraception (oral contraceptives, intrauterine device, contraceptive skin patch,&#xD;
             etc) during the treatment period and one month thereafter. In addition, they must have&#xD;
             a negative pregnancy test prior to treatment.&#xD;
&#xD;
          -  Any conditions that may be associated with a risk of poor protocol compliance.&#xD;
&#xD;
          -  Patients currently receiving regular ultraviolet radiation therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolf M Szeimies, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik und Poliklinik für Dermatologie, Klinikum der Universität Regensburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ashish C. Bhatia</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joseph Fowler</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert T. Matheson</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steven A. Davis</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautklinik Heinrich Heine Universität</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40223</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Winfried Klövekorn</name>
      <address>
        <city>Gilching</city>
        <zip>82205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Dermatologie und Venerologie Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München, Klinikum und Poliklinik für Dermatologie und Allergologie</name>
      <address>
        <city>Munchen</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Dermatologie, Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Klemm</name>
      <address>
        <city>Tutzing</city>
        <zip>82327</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pariser DM, Lowe NJ, Stewart DM, Jarratt MT, Lucky AW, Pariser RJ, Yamauchi PS. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol. 2003 Feb;48(2):227-32.</citation>
    <PMID>12582393</PMID>
  </reference>
  <reference>
    <citation>Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, Thai KE, Murrell D, Weightman W, Anderson C, Reid C, Watson A, Foley P. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat. 2003 Jun;14(2):99-106.</citation>
    <PMID>12775317</PMID>
  </reference>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>March 16, 2006</study_first_submitted>
  <study_first_submitted_qc>March 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <last_update_submitted>September 1, 2010</last_update_submitted>
  <last_update_submitted_qc>September 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2010</last_update_posted>
  <keyword>Methyl aminolevulinate</keyword>
  <keyword>Photodynamic therapy</keyword>
  <keyword>Aktilite CL128 LED light source</keyword>
  <keyword>Multiple Actinic Keratosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

